AstraZeneca Gestione

Gestione criteri di controllo 3/4

AstraZeneca Il CEO è Pascal Soriot, nominato in Oct2012, e ha un mandato di 12.08 anni. la retribuzione annua totale è $ 21.48M, composta da 8.5% di stipendio e 91.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.014% delle azioni della società, per un valore di € 26.77M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9.4 anni e 7 anni.

Informazioni chiave

Pascal Soriot

Amministratore delegato

US$21.5m

Compenso totale

Percentuale dello stipendio del CEO	8.5%
Mandato del CEO	12.1yrs
Proprietà del CEO	0.01%
Durata media del management	9.4yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Pascal Soriot rispetto agli utili di AstraZeneca?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

Compensazione vs Mercato: La retribuzione totale di Pascal ($USD 21.48M ) è superiore alla media delle aziende di dimensioni simili nel mercato BG ($USD 4.40M ).

Compensazione vs guadagni: La retribuzione di Pascal è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Pascal Soriot (65 yo)

12.1yrs

Mandato

US$21,484,390

Compensazione

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% € 26.8m
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% € 10.0m
Pam Cheng	EVP of Global opt. & IT	9.4yrs	Nessun dato	Nessun dato
Andrew Barnett	Head of Investor Relations	no data	Nessun dato	Nessun dato
Jeffrey Pott	CHRO, Chief Compliance Officer	15.8yrs	Nessun dato	Nessun dato
Gonzalo Vina	Head of Global Media Relations	no data	Nessun dato	Nessun dato
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.8yrs	Nessun dato	Nessun dato
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	Nessun dato	Nessun dato
Leon Wang	Executive VP of International & China President	10.8yrs	Nessun dato	Nessun dato
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7.6yrs	Nessun dato	Nessun dato
David Fredrickson	Executive Vice-President of Oncology Business Unit	7.1yrs	Nessun dato	Nessun dato
Ruth March	Senior VP of Precision Medicine - R&D Oncology	5.8yrs	Nessun dato	Nessun dato

9.4yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di ZEG è esperto e expertise (durata media dell'incarico 9.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% € 26.8m
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% € 10.0m
Pam Cheng	EVP of Global opt. & IT	no data	Nessun dato	Nessun dato
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	Nessun dato	Nessun dato
Marcus Wallenberg	Non-Executive Director	25.6yrs	US$159.35k	0.0039% € 7.3m
Philip John Broadley	Senior Independent Non-Executive Director	7.6yrs	US$254.96k	0.00052% € 974.7k
Michel Demare	Independent Chairman	5.2yrs	US$744.49k	0.00065% € 1.2m
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.9yrs	US$152.98k	0.000060% € 112.5k
Sherilyn S. McCoy	Independent Non-Executive Director	7.1yrs	US$223.09k	0.00011% € 206.2k
Euan Ashley	Independent Non-Executive Director	4.1yrs	US$151.70k	0.000070% € 131.2k
Shu Kam Mok	Independent Non-Executive Director	5.8yrs	US$140.23k	0.00013% € 243.7k
Nazneen Rahman	Independent Non-Executive Director	7.4yrs	US$203.97k	0.000070% € 131.2k

7.0yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ZEG sono considerati esperti (durata media dell'incarico 7 anni).

AstraZeneca Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media